Medical device PR is communications that stays inside what FDA has cleared, approved or classified for the device. A 510(k), PMA or De Novo decision sets the intended use, and every launch release, executive quote, influencer post and recall statement has to match it. FDA regulates device labeling and restricted-device ads, while the FTC polices most other device advertising.
Last updated: November 15, 2026
In this guide
- What do 510(k), PMA and De Novo mean for PR?
- Who regulates medical device advertising, FDA or the FTC?
- What can a medical device launch announcement say?
- How should device companies handle claims, data and testimonials?
- What should a medical device recall statement include?
- How do you build a medical device PR plan?
- What does medical device PR cost?
- Summary: what to settle before the first press release
- Frequently asked questions
What do 510(k), PMA and De Novo mean for PR?
The three main FDA marketing pathways for medical devices each set a different ceiling for what a communications team can say. FDA oversees devices on a risk basis, so the devices that pose the highest risk to patients face the most rigorous requirements before they can be legally marketed in the United States, according to the agency's overview of the 510(k) clearance process.
A premarket approval (PMA) is for high risk devices, and its review standard relies on an independent demonstration of safety and effectiveness. A 510(k) is for low to moderate risk devices that have a legally marketed predicate, and its review standard is comparative. A De Novo request is for low to moderate risk devices with no predicate.
| Pathway | Device risk | FDA decision | Wording for press materials |
|---|---|---|---|
| 510(k) | Low to moderate, predicate exists | Clearance | "FDA cleared," limited to the cleared indications |
| De Novo | Low to moderate, no predicate | Classification granted | "FDA granted De Novo classification," limited to the stated use |
| PMA | High | Approval | "FDA approved," limited to the approved indications |
FDA's own pages use "clearance" for a 510(k) and "approval" for a PMA, and press materials should follow the same words. Reporters can check a clearance claim in FDA's searchable releasable 510(k) database, so calling a cleared device "FDA approved" invites a correction request.
The submission itself is large. FDA reports that the average 510(k) submission has more than doubled in page count since 2009 and now runs over 1,000 pages. Communications teams should treat clearance timing as a regulatory affairs call and ask for status in writing instead of planning a launch date around a guess.
Who regulates medical device advertising, FDA or the FTC?
FDA controls the labeling of all medical devices, but it directly regulates advertising only for prescription drugs and restricted devices, while the Federal Trade Commission has primary jurisdiction over advertising for other devices. That split comes from a 2021 Food and Drug Law Institute (FDLI) training presentation on device promotion, and it shapes who can challenge a launch claim.
| Authority | What it covers | What it means for a launch |
|---|---|---|
| FDA | Labeling of all devices and advertising of restricted devices | Claims must fit the cleared or approved use, and restricted-device ads need a brief statement of intended use and relevant warnings, precautions, side effects and contraindications |
| FTC | Advertising of non-restricted devices | Claims need valid scientific evidence, and false or misleading ads are prohibited |
| Other enforcers | State attorneys general, DOJ, OIG, competitors and plaintiffs | Promotion can also draw Lanham Act suits, product liability claims and congressional attention, per an April 2022 FDLI presentation |
The working rule in the FDLI material is that a device may be labeled and promoted only for its cleared or approved intended uses. That rule matters for PR because FDA treats promotion as evidence of intended use. When labeling or advertising pushes a use outside the clearance, the device can be treated as misbranded or adulterated, and the new use may need its own 510(k) or PMA supplement.
A warning letter quoted in the 2022 FDLI presentation shows the pattern. FDA said a company's promotion of the Strattice Reconstructive Tissue Matrix, cleared under K082176 for soft tissue reinforcement, was evidence that the device was intended for breast reconstruction. The lesson for a communications team is that a case study, a conference talk or a press quote can create the intended use even when the product label never changed.
Drug and device rules differ in ways that matter for agencies working across healthcare. For the drug side, see how pharma ad enforcement letters work and how FDA complete response letter disclosure changes biotech communications.
What can a medical device launch announcement say?
A launch announcement can state the device name, the FDA pathway, the cleared indications for use and the clinical need, and it should leave out any claim of benefit beyond those indications. The safest process is to build the release from the clearance letter or approval order and have regulatory affairs sign off on each sentence.
- Use the exact indications for use from the clearance or approval, not a shortened version that widens the patient group.
- Write "FDA cleared" for 510(k) devices and "FDA approved" for PMA devices.
- Tie every performance number to a named study, patient group and endpoint, and confirm the patients studied fall inside the indications.
- Keep investor, sales, social and press language identical, because FDA reads all of it as evidence of intended use.
- Ask counsel before showing a device with a pending 510(k) at a trade show. The FDLI presentation says FDA Compliance Policy Guide 300.600 allows display only for the use in the pending notice.
Launch timing also depends on the audience. Clinicians read trade and journal coverage, hospital buyers read procurement and value analysis material, and patients read consumer health desks. For software-driven products, the digital health and health technology practice and the health tech product launch guide cover the added HIPAA and data questions.
How should device companies handle claims, data and testimonials?
Device companies should treat each performance claim, comparison and testimonial as a separate regulatory risk, because an FDA clearance covers the intended use but does not substantiate a specific number. In an August 2025 client alert, the law firm Loeb & Loeb wrote that FDA may clear a general use such as pain relief, but a specific claim such as a stated percentage of pain reduction must meet the FTC's substantiation standard.
The same alert said brands must make sure that influencer, consumer and expert endorsements stay consistent with the cleared intended use and the company's own substantiation. A creator who says a device "fixed" a condition outside the indications puts the brand at risk even if the brand never wrote the sentence.
Comparative claims carry their own rule. A Hogan Lovells article published by MDDI states that comparative claims must be truthful and not misleading, and that FDA may treat a comparison as misleading when it sets an unapproved use of one product against the approved use of another.
| Claim type | What it needs before release | Main risk |
|---|---|---|
| Indication statement | Wording copied from the clearance or approval | New intended use |
| Performance number | Named study, population inside the indications, substantiation on file | Overstated efficacy |
| Competitor comparison | Similar cleared or approved indications and head-to-head data | Misleading comparison |
| Testimonial or influencer post | Consistency with the cleared use and internal evidence | Off-label implication |
What should a medical device recall statement include?
A medical device recall statement should name the affected devices, describe the problem, tell users and clinicians what to do and give a contact for help, and its tone should fit the class FDA assigns to the recall. FDA uses the word recall when a manufacturer takes a correction or removal action to address a problem that violates FDA law, and a recall does not always mean users must stop using the product.
FDA says that for an implanted device, a recall does not always mean explant. Companies often tell doctors to contact patients to weigh the risk of removal against the risk of leaving the device in place. A statement that skips this distinction can send patients into emergency rooms for no reason.
| Recall class | FDA description | Public communication |
|---|---|---|
| Class I | A reasonable chance the product will cause serious health problems or death | FDA posts consumer information on Class I recalls |
| Class II | The product may cause a temporary or reversible problem, or there is a slight chance of serious problems | FDA posts consumer information on some Class II recalls |
| Class III | The product is not likely to cause any health problem or injury | Recorded in FDA's recall database and weekly Enforcement Report once classified |
The usual sequence is that the company starts the recall and notifies FDA. FDA reviews the strategy, assesses the hazard, assigns a class and monitors the action until it is effective, according to FDA's page on medical device recalls. FDA can order a recall but says it has rarely needed to. The agency adds that fewer than 2% of 510(k) devices face a class I or class II recall in a year, so recall readiness is mostly about having approved text ready before it is needed.
A holding statement, an owner for each audience and a clear escalation chain are the core pieces. The crisis PR practice covers how those pieces fit together under pressure.
How do you build a medical device PR plan?
A medical device PR plan starts with a written claims map from regulatory affairs and ends with a recall holding statement, in six steps.
- Get the indications for use, the clearance or approval date and the list of allowed claims in writing from regulatory affairs.
- Build a claims library with approved sentences, the evidence behind each one and the study it comes from.
- Set a review rule so that regulatory and legal teams check every release, social post and spokesperson talking point before it goes out.
- Prepare clinician spokespeople who can speak to the cleared use without drifting into other uses, and brief them on what not to say.
- Pitch trade, clinical and consumer health reporters with different angles, and give each one the clearance language and the study details.
- Write the recall holding statement and the contact chain in advance, and check how AI search answers describe the device's indication so errors can be corrected at the source.
The broader healthcare PR practice handles hospitals, payers and device makers under the same rules. Brands can also review 5W's pharma and Rx AI Visibility Index to see how regulated healthcare brands appear in AI answers.
What does medical device PR cost?
Medical device PR retainers at 5W start at around $15,000 per month, and the final price depends on the number of devices, the regulatory review workload and the event calendar. A company with one cleared device and one trade show needs less than a company with several products across multiple pathways. The healthcare PR cost guide lays out what drives the price and what bills extra.
Summary: what to settle before the first press release
Medical device PR works when every public statement matches the cleared, approved or classified intended use. Four decisions come first:
- Which pathway the device used, and which FDA term applies: cleared, approved or classified through De Novo.
- Whether FDA or the FTC has primary jurisdiction over the advertising.
- Which claims have evidence on file, and who signs off on each one.
- What the recall statement says, and who sends it.
Regulatory affairs and counsel should review the final text of every item above, since this guide covers communications practice and does not replace their advice.
Frequently asked questions
Is a 510(k) device "FDA approved"?
No. FDA clears devices through the 510(k) pathway and approves devices through the PMA pathway, and its own pages use those two words. A 510(k) device should be described as FDA cleared, and the claim should stay within the cleared indications.
Can a company announce a device before FDA clearance?
A company can discuss development status, but FDA looks at labeling, advertising and spoken or written statements when it decides a device's intended use. Any announcement made before clearance needs regulatory and legal review first, and it should not claim safety or effectiveness for a use FDA has not cleared.
Does every device recall need a press release?
No. FDA says it may post company press releases for recalls that present significant risks, and it posts consumer information on Class I recalls and some Class II and III recalls. The company decides on public notification with regulatory counsel, based on the recall class and whether patients need to act.
How is device PR different from pharma PR?
Device claims follow the 510(k), PMA or De Novo decision, while drug claims follow the drug approval. FDA directly regulates prescription drug advertising and restricted device advertising, and the FTC regulates most other device advertising, so a device launch often faces a different regulator than a drug launch does.
How much does medical device PR cost?
5W PR retainers start at around $15,000 per month. Scope drives the final figure, including the number of devices, how many pathways are in play and how much regulatory review each release needs.
